Literature DB >> 6861264

Decreased plasma half-life of cyclophosphamide during repeated high-dose administration.

M I Graham, I C Shaw, R L Souhami, B Sidau, P G Harper, A E McLean.   

Abstract

Cyclophosphamide was given as IV doses of 50 mg/kg/day on each of four successive days as treatment for ovarian and lung cancer. Blood samples were taken at regular intervals and analysed for cyclophosphamide by gas liquid chromatography. The plasma half-lives (t 1/2) and volumes of distribution (V D) were calculated for each of the treatment days; t 1/2 was found to decrease with subsequent doses whereas V D was not significantly changed.

Entities:  

Mesh：

Substances：

Year:  1983        PMID： 6861264     DOI： 10.1007/bf00255760

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN： 0344-5704            Impact factor:   3.333


  8 in total

1.  Quantitative GLC determination of cyclophosphamide and isophosphamide in biological specimens.

Authors:  C Pantarotto; A Bossi; G Belvedere; A Martini; M G Donelli; A Frigerio
Journal:  J Pharm Sci       Date:  1974-10       Impact factor: 3.534

2.  Clinical pharmacology of cyclophosphamide.

Authors:  C M Bagley; F W Bostick; V T DeVita
Journal:  Cancer Res       Date:  1973-02       Impact factor: 12.701

3.  Intensive cyclophosphamide (NSC-26271) therapy for solid tumors.

Authors:  G M Mullins; M Colvin
Journal:  Cancer Chemother Rep       Date:  1975 Mar-Apr

4.  High-dose cyclophosphamide with autologous marrow transplantation as initial treatment of small cell carcinoma of the bronchus.

Authors:  R L Souhami; P G Harper; D Linch; C Trask; A H Goldstone; J Tobias; S G Spiro; D M Geddes; J D Richards
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

5.  Denaturation of cytochrome P-450 by cyclophosphamide metabolites.

Authors:  A J Marinello; H L Gurtoo; R F Struck; B Paul
Journal:  Biochem Biophys Res Commun       Date:  1978-08-29       Impact factor: 3.575

6.  Quantitation by gas chromatography-chemical ionization mass spectrometry of cyclophosphamide, phosphoramide mustard, and nornitrogen mustard in the plasma and urine of patients receiving cyclophosphamide therapy.

Authors:  I Jardine; C Fenselau; M Appler; M N Kan; R B Brundrett; M Colvin
Journal:  Cancer Res       Date:  1978-02       Impact factor: 12.701

7.  Decreased half life of cyclophosphamide in patients under continual treatment.

Authors:  M D'Incalci; G Bolis; T Facchinetti; C Mangioni; L Morasca; P Morazzoni; M Salmona
Journal:  Eur J Cancer       Date:  1979-01       Impact factor: 9.162

8.  Pharmacokinetics of cyclophosphamide in man.

Authors:  J L Cohen; J Y Jao; W J Jusko
Journal:  Br J Pharmacol       Date:  1971-11       Impact factor: 8.739
  8 in total
  18 in total

1.  A mechanism-based pharmacokinetic-enzyme model for cyclophosphamide autoinduction in breast cancer patients.

Authors:  M Hassan; U S Svensson; P Ljungman; B Björkstrand; H Olsson; M Bielenstein; M Abdel-Rehim; C Nilsson; M Johansson; M O Karlsson
Journal:  Br J Clin Pharmacol       Date:  1999-11       Impact factor: 4.335

Review 2.  Ifosfamide/mesna. A review of its antineoplastic activity, pharmacokinetic properties and therapeutic efficacy in cancer.

Authors:  K L Dechant; R N Brogden; T Pilkington; D Faulds
Journal:  Drugs       Date:  1991-09       Impact factor: 9.546

3.  The pharmacokinetics of high dose cyclophosphamide and high dose etoposide.

Authors:  D Cunningham; J Cummings; R B Blackie; L McTaggart; S W Banham; S B Kaye; M Soukop
Journal:  Med Oncol Tumor Pharmacother       Date:  1988

4.  Haematological recovery following high-dose cyclophosphamide with autologous bone marrow transplantation.

Authors:  C Twelves; R Souhami; P Harper; A Goldstone
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

Review 5.  Pharmacokinetic drug interactions of commonly used anticancer drugs.

Authors:  F M Balis
Journal:  Clin Pharmacokinet       Date:  1986 May-Jun       Impact factor: 6.447

6.  A cellular analysis of long-term haematopoietic damage in mice after repeated treatment with cyclophosphamide.

Authors:  G Molineux; C Xu; J Hendry; N G Testa
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

7.  Repeated high-dose cyclophosphamide administration in bone marrow transplantation: exposure to activated metabolites.

Authors:  U Schuler; G Ehninger; T Wagner
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

8.  Population pharmacokinetics analysis of cyclophosphamide with genetic effects in patients undergoing hematopoietic stem cell transplantation.

Authors:  In-Wha Kim; Hwi-yeol Yun; Boyoon Choi; Nayoung Han; Myeong Gyu Kim; Seonyang Park; Jung Mi Oh
Journal:  Eur J Clin Pharmacol       Date:  2013-04-16       Impact factor: 2.953

9.  Pharmacokinetics and metabolism of cyclophosphamide administered after total body irradiation of bone marrow transplant recipients.

Authors:  U Schuler; P Waidelich; H Kolb; T Wagner; G Ehninger
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

Review 10.  Ifosfamide pharmacokinetics.

Authors:  L D Lewis
Journal:  Invest New Drugs       Date:  1991-11       Impact factor: 3.850
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.